ClinicalTrials.gg
CompletedNCT03793023Updated Jan 27, 2025

Observational Study to Evaluate the Efficacy and Safety of Teneligliptin

An observational study in Type 2 Diabetes Mellitus, sponsored by Handok Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Handok Inc. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
2,983
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Diabetes Mellitus, Type 2 by Handok Inc. — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Handok Inc..

Started
2016
the only one that year
Observational
Only one
of the 15
Registered
12th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 2 by Handok Inc., this one is the only one that started in 2016, is the only observational one, and was the 12th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 15 studies in Diabetes Mellitus, Type 2 by Handok Inc. is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Diabetes Mellitus, Type 2 by Handok Inc. as a file.
02

Study summary

This study is designed as a prospective, observational, multi-centre study to evaluate the efficacy and safety of Teneligliptin when switched from other DPP-4 inhibitors in type 2 DM with inadequate glycemic control

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Type 2 DM patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is aged ≥19 years
  2. The subject has a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit.
  3. Patient who was treated with same dosage of DPP4 inhibitor for at least 12 weeks prior to baseline visit (if patient who has been treated with DPP4 inhibitor and any other antidiabetic drugs, antidiabetic drugs should also have been kept same dosage for at least 12 weeks prior to baseline.)
  4. Patient with ≥7.0% at baseline visit
  5. Patient who can be switched to Teneligliptin instead of using DPP-4 inhibitor for glycemic control based on the investigator's judgment
  6. Patient (or legal guardian, if applicable) is informed of the full nature and purpose of the study, including possible risks and side effects, and understand this information, voluntarily signed and dated the written in compliance with protocol before inclusion in the study

Exclusion criteria

Exclusion Criteria:

  1. Patient with to the Teneligliptin
  2. Patient who treat the Teneligliptin prior to baseline visit
  3. A pregnant or lactating female patient
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
2,983 participants (actual)
Patient registry
No

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    To assess change from baseline in glycated hemoglobin (HbA1c)

    Time frame: at 12 weeks after switching to Teneligliptin

Secondary outcomes

  1. Change in HbA1c

    To assess change from baseline in HbA1c

    Time frame: at 24, 52 weeks after switching to Teneligliptin

  2. Change in FBG

    To assess change from baseline in fasting blood glucose (FBG)

    Time frame: at 12, 24, 52 weeks after switching to Teneligliptin

  3. Change in body weight, BMI

    To assess change from baseline in body weight and body mass index (BMI)

    Time frame: at 12, 24, 52 weeks after switching to Teneligliptin

  4. Change in lipid profile(Total cholesterol, LDL cholesterol, HDL cholesterol)

    To assess change from baseline in serum lipid profile (total cholesterol, LDL and HDL cholesterol, triglyceride)

    Time frame: at 12, 24, 52 weeks after switching to Teneligliptin

  5. The percentage of patients with HbA1c <7.0% and <6.5%

    To assess the percentage of patients with HbA1c \<7.0% and \<6.5%

    Time frame: at Weeks 12, 24, and 52 of teneligliptin treatment

  6. The percentage of patients with a decrease from baseline in HbA1c

    To assess the percentage of patients with a decrease from baseline in HbA1c by ≥0.3% and ≥ 0.5%

    Time frame: at Weeks 12, 24, and 52 of teneligliptin treatment

  7. Safety Outcome

    To assess the safety of teneligliptin treatment(AE, ADR, SAE etc.)

    Time frame: at Weeks 12, 24, and 52 of teneligliptin treatment

07

Study locations

1 site
  • Ajou University Hospital
    Suwon, Gyeonggi, Korea, Republic of
08

References and documents

Publications

  • Kim HJ, Kim YS, Lee CB, Choi MG, Chang HJ, Kim SK, Yu JM, Kim TH, Lee JH, Ahn KJ, Kim K, Lee KW. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report. Diabetes Ther. 2019 Aug;10(4):1271-1282. doi: 10.1007/s13300-019-0628-0. Epub 2019 May 11. PubMed 31079357 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Sep 2019, 44 months.

Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2019
First posted
Jan 4, 2019
StartActual
Jan 5, 2016
Primary completionActual
Sep 23, 2019
CompletionActual
Sep 23, 2019
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03793023
Lead sponsor
Handok Inc.
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Jan 5, 2016
Primary completion
Sep 23, 2019
Completion
Sep 23, 2019
Last update
Jan 27, 2025

Study contacts

Kwan Woo Lee, MD, Ph.D
principal investigator · Ajou University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion